Portal de Periódicos da CAPES

Antipyretic drugs for children

2006; BMJ; Volume: 333; Issue: 7557 Linguagem: Inglês

10.1136/bmj.333.7557.4

0959-8138

Alastair D Hay, Niamh M Redmond, Margaret Fletcher,

Hemodynamic Monitoring and Therapy

key objective over the next two or three years is to create a dynamic environment for research and development within which doctors can work with suppliers and others on the new electronic services, can continue to innovate after the initial services have been delivered, and can, if necessary, take part in decisions to amend or stop unsuccessful developments.Staff working on the programme face a dilemma, however.How can they retain the advantages of the central procurement arrangements while at the same time encouraging localism?The answer may be for Connecting for Health, the agency responsible for the programme, to become a regulator.The agency could stop directing implementation centrally and could become responsible for encouraging good working relationships between suppliers and clinicians.In this way the agency would retain its role in monitoring compliance with multibillion pound contracts while letting clinicians and suppliers get on with development.It would also have an ongoing role in protecting the wider public interest on matters such as patient confidentiality.This arrangement might help to allay some clinicians' natural fears that their concerns will not be taken into account in the rush to computerisation.